Ascentage to release new clinical data at the 2019 ASCO Annual Meeting

• The company intends to present three abstracts at the event on the same day.
• The clinical data would be presented at poster board 116, 117 and 118 respectively.

Ascentage Pharma Group Corporation, Ltd., (Ascentage Pharma), a renowned clinical-stage biotechnology firm, has reportedly announced that it would be presenting new data from the clinical study of its investigational apoptosis-targeted drugs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Reports cite, the company intends to present three abstracts, namely study of APG-115 on patients with Soft Tissue Sarcomas, APG-115 on Advanced Solid Tumors and APG-1387 on Advanced Solid Tumors, at the event on the same day. According to a press release from Ascentage Pharma, the APG-115, a new MDM2-P53 Antagonist, showed promising anti-tumor activity when treating patients suffering from MDM2-amplification & TP53-WT liposarcoma and was well-tolerated and had adverse events that were manageable. However, while APG-1387, a new IAP Inhibitor, was well-tolerated, it requires further exploration. The Chief Medical Officer at Ascentage Pharma, Yifan Zhai, M.D., Ph.D., stated that the company is thrilled to present the progress it has made in all three of its clinical studies. Dr. Zhai further added that the presentations would be demonstrating the company’s capabilities in moving multiple novel drug candidates in clinical development across several different cancer patient populations. The company, through its agile development capabilities and breakthrough science, is reportedly striving to facilitate new medicinal products with differentiated profiles to bring health benefits to patients. For the record, APG-115 is presently in Phase 1 clinical trial in the U.S. and China in patients suffering from Adenoid cystic carcinoma as well as other sarcomas. Meanwhile, the APG-1387 has completed its Phase 1 dose escalation clinical trials in Australia and China with a Phase 1 pembrolizumab- APG-1387 combination currently underway in the U.S. According to reports, the data would be presented on Saturday, June 1^st during the morning session. Source Credit: https://www.ascentagepharma.com/press-releases/ascentage-pharma-to-present-new-data-at-2019-asco-annual-meeting-from-clinical-trials-of-mdm2-p53-antagonist-and-iap-inhibitor-in-cancers/